EUVIMEDEUVIMED entdecken
Crossref

Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr

Stanislav A Petrov iD, Gleb P Grigoriev, Grigory A Orlov, Nikolay Y Zyk, Yuri K Grishin, Vitaly A Roznyatovsky, Maria A Beloglazkina, Juliana V Petrova iD, Aleksei E Machulkin iD, Mariia S Larkina iD, Anastasia Prach, Ruslan Varvashenya und 4 weitere

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Stanislav A Petrov und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia. Hauptthemen laut MEDLINE: Glutamate Carboxypeptidase II, Antigens, Surface, Heterocyclic Compounds, 1-Ring, Receptors, Bombesin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: Russian Science Foundation, Lomonosov Moscow State University, RUDN University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Heterodimeric approaches have emerged as a promising method for simultaneously targeting multiple receptors on tumor cells using a single molecule. Simultaneous targeting of the prostate-specific membrane antigen (PSMA) and the gastrin-releasing peptide receptor (GRPr) holds the potential to improve the accuracy of prostate cancer diagnosis. The aim of this study was to develop a convenient and simple modular strategy for the creation of heterobivalent (HBV) conjugates targeting PSMA/GRPr receptors. For this purpose, we developed and compared six alternative routes for the stereoselective synthesis of HBV conjugates designed to deliver the chelating agent DOTA to PSMA/GRPr receptors. The comparison of these alternative synthetic pathways took into account such factors as efficiency, complexity, synthesis, and purification details, as well as yields of the target compounds. Optimal conditions for the stereoselective synthesis of HBV ligands to PSMA and GRPr, which could serve as molecular platforms for the targeted delivery of therapeutic or diagnostic agents to these receptors, were revealed. For synthesized HBV ligand 26x and its HBV conjugate with DOTA 27, the complete signal assignment in 1H, 13C, and 15N NMR spectra was achieved using 2D NMR techniques. Based on these data, comprehensive signal assignments were provided for all final compounds in their NMR spectra. The final HBV conjugate 27 was labeled with Lu-177, with yields >99%, and the obtained radiotracer was studied in vitro for its binding specificity, with determining of the KD and Bmax using LNCaP (PSMA+) and PC-3 (GRPr+) cell lines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glutamate Carboxypeptidase IIAntigens, SurfaceHeterocyclic Compounds, 1-RingReceptors, BombesinRadiopharmaceuticalsHumansProstatic NeoplasmsMaleChelating AgentsCell Line, TumorLigands

Substanzen

Glutamate Carboxypeptidase IIFOLH1 protein, human1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidAntigens, SurfaceHeterocyclic Compounds, 1-RingReceptors, BombesinRadiopharmaceuticalsChelating AgentsLigands

Autor:innen und Institutionen

  • Department of Chemistry, Lomonosov Moscow State University, Moscow 119991, Russia.
  • Department of Organic Chemistry, People's Friendship University of Russia Named after Patrice Lumumba (RUDN University), Moscow 117198, Russia.
  • Department of Biochemistry, People's Friendship University of Russia Named After Patrice Lumumba (RUDN University), Moscow 117198, Russia.
  • Research Centrum for Oncotheranostics, Research School of Chemistry and Applied Biomedical Sciences, Tomsk Polytechnic University, Tomsk 634050, Russia.
  • Scientific and Educational Laboratory of Chemical and Pharmaceutical Research, Siberian State Medical University, Tomsk 634050, Russia.
  • The Laboratory of Molecular Therapy of Cancer, Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk 634050, Russia.

ORCID-Profile: Stanislav A Petrov, Juliana V Petrova, Aleksei E Machulkin, Mariia S Larkina, Elena K Beloglazkina

Förderung

  • Russian Science Foundation
  • Lomonosov Moscow State University
  • RUDN University

Zitieren

APA

Petrov, S. A., Grigoriev, G. P., Orlov, G. A., Zyk, N. Y., Grishin, Y. K., Roznyatovsky, V. A., Beloglazkina, M. A., Petrova, J. V., Machulkin, A. E., Larkina, M. S., Prach, A., Varvashenya, R., Bodenko, V., Plotnikov, E., Yusubov, M. S., & Beloglazkina, E. K. (2025). Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00033

Vancouver

Petrov SA, Grigoriev GP, Orlov GA, Zyk NY, Grishin YK, Roznyatovsky VA, et al. Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00033

BibTeX
@article{Petrov2025,
  author = {Petrov, Stanislav A and Grigoriev, Gleb P and Orlov, Grigory A and Zyk, Nikolay Y and Grishin, Yuri K and Roznyatovsky, Vitaly A and Beloglazkina, Maria A and Petrova, Juliana V and Machulkin, Aleksei E and Larkina, Mariia S and Prach, Anastasia and Varvashenya, Ruslan and Bodenko, Vitalina and Plotnikov, Evgenii and Yusubov, Mekhman S and Beloglazkina, Elena K},
  title = {Choice of an Optimal Modular Strategy for the Synthesis of DOTA-Containing Heterobivalent Agents Targeting PSMA and GRPr},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00033}
}
Kostenlos starten →